Curated News
By: NewsRamp Editorial Staff
August 14, 2026
HeartBeam Advances Heart Attack Detection, Reports Q2 2026 Results
TLDR
- HeartBeam's early ALIGN-ACS completion and initial commercial orders give it a first-mover edge in portable 12-lead ECG.
- HeartBeam's ALIGN-ACS enrolled 134 patients early; HEADSTART-ACS over 50%; prototype done; cash $8.8M, burn under $14M.
- HeartBeam's cable-free 3D ECG enables at-home cardiac monitoring, potentially saving lives by detecting heart attacks earlier.
- HeartBeam's 3D ECG captures signals from three directions, synthesizing a 12-lead ECG without cables—a medical breakthrough.
Impact - Why it Matters
HeartBeam's progress in developing a portable 3D ECG device could revolutionize how heart attacks and arrhythmias are detected, potentially saving lives by enabling timely intervention outside traditional medical settings. For investors, the completion of key clinical milestones and initial commercial rollout signal the company's transition from development to market entry, which could lead to significant growth opportunities in the cardiac monitoring space.
Summary
HeartBeam (NASDAQ: BEAT), a medical technology company specializing in 3D ECG technology, has announced its second-quarter 2026 financial and operational results, showcasing significant strides in its heart attack detection program, the development of a 12-lead ECG extended wear patch, and the initial commercial launch. The company has completed enrollment of 134 patients in its ALIGN-ACS pilot study ahead of schedule, with full results expected to be presented at TCT 2026, and has surpassed 50% enrollment in its 500-patient HEADSTART-ACS pilot study. Additionally, HeartBeam has completed a working prototype of its 12-lead ECG extended wear patch, signed multiple commercial agreements across four targeted U.S. geographies, shipped its first orders, and onboarded initial patients.
Financially, HeartBeam reported a second-quarter net loss of $5 million, or $0.10 per basic and diluted share, consistent with the prior year's net loss of $5 million, or $0.15 per share. The company's cash position remains robust with $8.8 million in cash, cash equivalents, and restricted cash as of June 30, 2026, and it expects full-year 2026 net operating cash outflow to be below $14 million.
HeartBeam's innovative platform aims to transform cardiac care by enabling the collection of ECG signals in 3D from three non-coplanar directions, synthesizing them into a 12-lead ECG, all in a cable-free device. This technology received FDA clearance for arrhythmia assessment in December 2024 and for 12-lead ECG synthesis software in December 2025. With over 20 issued patents, HeartBeam is positioned to redefine cardiac health management outside medical facilities. For more details, visit the full press release at https://ibn.fm/QjrtT and explore the company's newsroom at https://ibn.fm/BEAT.
Source Statement
This curated news summary relied on content distributed by InvestorBrandNetwork (IBN). Read the original source here, HeartBeam Advances Heart Attack Detection, Reports Q2 2026 Results
